Latest filing published 21 Aug 2026 for Arcutis Biotherapeutics, Inc., €40k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Patrick Burnett in Arcutis Biotherapeutics, Inc. Between 30 December 2021 and 19 August 2026, the trades on record add up to 45 filings.
On the market, this insider has only sold: 33 sales, €3.5M in total. Outside the open market, there are 6 share grants and 6 option exercises. 2026 to date brings no purchases and 9 sales.
The newest entry dates from 21 August 2026: an open-market sale of €40k, in Arcutis Biotherapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 45 declarations